Clinical Trial

RIC-NEC Randomized Controlled Trial

Study acronym: RIC-NEC
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Necrotizing enterocolitis (NEC) is a serious intestinal disease of preterm and term neonates which remains a major cause of intestinal failure, and an unsolved clinical challenge in pediatrics. While overall mortality of preterm infants continues to decrease due to improvements in general neonatal care, mortality caused by NEC remains high (up to 30-50%) and survivors suffer from reduced quality of life, and long-term disabilities such as debilitating complications of intestinal failure, poor growth and neurodevelopmental delay. Besides prevention, there have been hardly any innovations in the treatment of NEC which underwent trial evaluation. NEC pathogenesis is multifactorial, but bowel ischemia is known to play an essential role in the development of NEC. Remote ischemic conditioning (RIC) is a therapeutic maneuver that involves brief cycles of non-lethal ischemia and reperfusion applied to a limb, which protects distant organs (such as the intestine) from ischemic damage. The investigators have shown that in preclinical models of NEC, RIC effectively reduces intestinal damage and prolongs survival. The investigators have also demonstrated the safety of RIC in preterm neonates with NEC. Before the investigators can evaluate the effectiveness of RIC in treating neonates with NEC in a Phase III randomized clinical trial (RCT), a Phase II Feasibility RCT must be conducted to evaluate issues related to the enrollment and randomization of neonates, masking of the RIC intervention, and measurement of clinical outcomes. The investigators hypothesize that it is feasible to conduct a multicenter RCT to evaluate RIC during the management of neonates with medical NEC.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-03-06; most recent amendment 2026-01-30.
Status change: Recruiting → Active, Not Recruiting 2026-01-30
Status change: Not Yet Recruiting → Recruiting 2024-01-08
Trial Details
NCT Number NCT05279664
Lead Sponsor The Hospital for Sick Children
Collaborators: Thrasher Research Fund, Mount Sinai Hospital, Canada, Sunnybrook Health Sciences Centre, McMaster Children's Hospital, Children's Hospital Medical Center, Cincinnati, Children's Hospital of Orange County, Karolinska University Hospital, Sophia Kindergeneeskunde, UCL Great Ormond Street Institute of Child Health, Hospital Universitario La Paz, University of Southampton, Xiamen Children's Hospital, Fujian of China, Shanghai Children's Hospital
Conditions Necrotizing Enterocolitis
Enrollment 78 participants
Start Date 2023-02-09
Primary Completion 2025-12-20 (estimated)
Study Completion 2026-03-18 (estimated)
Updated on ClinicalTrials.gov 2026-02-03